Back to Search
Start Over
Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection
- Source :
- Bone marrow transplantation. 34(8)
- Publication Year :
- 2004
-
Abstract
- Up to a third of autologous transplantation candidates fail to mobilize hematopoietic progenitors into the peripheral blood with chemotherapy and/or growth factor treatment, thus requiring innovative mobilization strategies. In total, 20 cancer patients unable to provide adequate PBPC products after a previous mobilization attempt were treated with ancestim (20 microg/kg/day s.c.) and filgrastim (10 microg/kg/day s.c.). In 16 patients, the pre-study mobilization was with filgrastim alone. Eight patients underwent single large volume leukapheresis (LVL) and 12 multiple standard volume leukaphereses (SVL) in both mobilizations. Pairwise comparison of peripheral blood CD34(+) cell concentrations on the day of first leukapheresis failed to document synergism - median CD34(+)/microl of 3.2 (
- Subjects :
- Adult
Male
medicine.medical_specialty
Time Factors
Filgrastim
Urology
Blood volume
Antigens, CD34
Transplantation, Autologous
Granulocyte Colony-Stimulating Factor
Medicine
Autologous transplantation
Humans
Leukapheresis
Hematopoietic Stem Cell Mobilization
Ancestim
Transplantation
Stem Cell Factor
biology
business.industry
Stem Cells
Hematology
Middle Aged
Recombinant Proteins
Surgery
Granulocyte colony-stimulating factor
biology.protein
Leukocytes, Mononuclear
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 02683369
- Volume :
- 34
- Issue :
- 8
- Database :
- OpenAIRE
- Journal :
- Bone marrow transplantation
- Accession number :
- edsair.doi.dedup.....c9a73086f951ec6a385a362822e8e363